Novartis has announced that the EMA has granted license for the use of Aimovig® (erenumab) for the prevention of migraine in adults.
Aimovig® (erenumab) has received a positive opinion from the CHMP for migraine, steering the way towards a marketing authorization from the EMA.
Novartis and Amgen have announced that Aimovig® has been approved by the US FDA for the preventive treatment of migraine in adults.
In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis.
A preliminary study has revealed that a monoclonal antibody could prevent difficult-to-treat migraines in patients who have tried unsuccessfully to prevent them using other treatments.
Clinical trial announcements, orphan-drug designation and more: check out our round-up of the biggest news from the neuroscience and neurology industries this week.
The latest study assessing the drug erenumab has demonstrated promising results for migraine sufferers who failed to respond to prior treatments.
A study at University Hospital Mannheim and Heidelberg University has indicated that migraine sufferers have significantly higher concentrations of sodium present in their cerebrospinal fluid than non-sufferers.
Data from a head-to-head, open-label study were presented at the 18th Congress of the International Headache Society in Vancouver (Canada, 7–10 September 2017).